Loading
Etoposide / Extensive Stage Small Cell Lung Cancer / Atezolizumab · Phase 3 Trial
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered Phase 3 trial comparing BMS-986489 (anti-fucosyl-GM1 plus nivolumab) combined with carboplatin and etoposide against atezolizumab with the same chemotherapy as first-line treatment in extensive-stage small cell lung cancer. The study is currently recruiting and has not yet reported results, so efficacy and safety cannot be evaluated from this registry entry.
Phase 3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Extensive-Stage Small Cell Lung Cancer; age from 18 Years. Intervention: Arm A. Compared with: Arm B — Active Comparator. n = 530. 183 sites across 26 countries.
This is a registered Phase 3 trial comparing BMS-986489 (anti-fucosyl-GM1 plus nivolumab) combined with carboplatin and etoposide against atezolizumab with the same chemotherapy as first-line treatment in extensive-stage small cell lung cancer. The study is currently recruiting and has not yet reported results, so efficacy and safety cannot be evaluated from this registry entry.
Registry record only; no efficacy or safety results are reported. No interim analyses or preliminary safety signals are disclosed.
The source did not state who this applies to in practice.
This is a Phase 3 trial registration with no results reported; the study is actively recruiting and outcome data are not yet available.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06646276). This is a study registration, not published results. Lead sponsor: Bristol-Myers Squibb. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 530 participants (ESTIMATED). Conditions: Extensive-Stage Small Cell Lung Cancer. Interventions: BIOLOGICAL: BMS-986489 (BMS-986012+Nivolumab); BIOLOGICAL: Atezolizumab; DRUG: Carboplatin; DRUG: Etoposide. Primary outcome measures: Overall Survival (OS) , Up to 5 years. Brief summary: The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.